202 related articles for article (PubMed ID: 38442719)
1. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
[TBL] [Abstract][Full Text] [Related]
2. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
[TBL] [Abstract][Full Text] [Related]
3. Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.
Choe YJ; Ahn YH; Gwak E; Jo E; Kim J; Choe SA
Pediatr Nephrol; 2024 Feb; 39(2):625-629. PubMed ID: 37880380
[TBL] [Abstract][Full Text] [Related]
4. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
Chen C; Chen C; Cao L; Fang J; Xiao J
Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382
[TBL] [Abstract][Full Text] [Related]
5. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Min YG; Hong YH; Song TJ
J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
[TBL] [Abstract][Full Text] [Related]
7. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines.
Foltran D; Delmas C; Flumian C; De Paoli P; Salvo F; Gautier S; Drici MD; Karsenty C; Montastruc F
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):99-103. PubMed ID: 34849667
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
Jeong HS; Chun BC
PLoS One; 2024; 19(2):e0297902. PubMed ID: 38381729
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
[TBL] [Abstract][Full Text] [Related]
10. Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level.
Chouchana L; Blet A; Al-Khalaf M; Kafil TS; Nair G; Robblee J; Drici MD; Valnet-Rabier MB; Micallef J; Salvo F; Treluyer JM; Liu PP
Clin Pharmacol Ther; 2022 Mar; 111(3):605-613. PubMed ID: 34860360
[TBL] [Abstract][Full Text] [Related]
11. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA
Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.
Kim S; Bea S; Choe SA; Choi NK; Shin JY
Eur J Clin Pharmacol; 2024 Mar; 80(3):445-453. PubMed ID: 38212538
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination.
Chua GT; Kwan MYW; Chui CSL; Smith RD; Cheung ECL; Ma T; Leung MTY; Tsao SSL; Kan E; Ng WKC; Chan VCM; Tai SM; Yu TC; Lee KP; Wong JSC; Lin YK; Shek CC; Leung ASY; Chow CK; Li KW; Ma J; Fung WY; Lee D; Ng MY; Wong WHS; Tsang HW; Kwok J; Leung D; Chung KL; Chow CB; Chan GCF; Leung WH; To KKW; Yuen KY; Lau YL; Wong ICK; Ip P
Clin Infect Dis; 2022 Sep; 75(4):673-681. PubMed ID: 34849657
[TBL] [Abstract][Full Text] [Related]
16. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
Chen C; Fu F; Ding L; Fang J; Xiao J
Front Immunol; 2022; 13():938322. PubMed ID: 36172346
[TBL] [Abstract][Full Text] [Related]
17. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
Lee H; Kim HJ; Choe YJ; Shin JY
Vaccine; 2020 Jul; 38(34):5464-5473. PubMed ID: 32600907
[TBL] [Abstract][Full Text] [Related]
18. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination.
Piché-Renaud PP; Morris SK; Top KA
Br J Clin Pharmacol; 2023 Mar; 89(3):967-981. PubMed ID: 36480113
[TBL] [Abstract][Full Text] [Related]
19. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
